TY -的T1 Tiotropium在儿科哮喘摩根富林明- European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02034-2016 VL - 49 IS - 1 SP - 1602034 AU - Grigg, Jonathan Y1 - 2017/01/01 UR - //www.qdcxjkg.com/content/49/1/1602034.abstract N2 - The emerging evidence that there are many types of asthma that may respond differently to treatment suggests a need for novel inhaled therapies beyond the current armamentarium of short-acting β2-agonists, long-acting β2-agonists (LABA) and inhaled corticosteroids (ICS). Recent phase III trials suggest that tiotropium, a long-acting muscarinic antagonist, is a promising treatment for adult asthma. In this patient population, two recent Cochrane reviews have evaluated: 1) adding tiotropium to LABA/ICS combinations in patients whose asthma is not well controlled by LABA/ICS alone; and 2) adding tiotropium to ICS compared with adding a LABA to ICS.No significant benefit of inhaled tiotropium was found in a trial in children and young people with severe asthma http://ow.ly/jmK1306ck1N ER -